Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Ipilimumab + Nivolumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ipilimumab | Yervoy | BMS-734016 | CTLA4 Antibody 17 Immune Checkpoint Inhibitor 94 | Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
| Nivolumab | Opdivo | MDX-1106|BMS-936558 | Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63 | Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer, small cell lung cancer, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and esophageal squamous cell carcinoma, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | renal cell carcinoma | not applicable | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase III trial (CheckMate 214) that supported FDA approval, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) resulted in improved median overall survival (not reached vs. 26.0 months), objective response rate (42%, 40 complete responses (CR), vs. 27%, 5 CR), and progression-free survival (11.6 vs 8.4 months) compared to Sutent (sunitinib) in patients with intermediate or poor risk renal cell carcinoma (PMID: 29562145; NCT02231749). | 29562145 detail... detail... |
| Unknown unknown | renal cell carcinoma | not applicable | Ipilimumab + Nivolumab | Phase I | Actionable | In a Phase I trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated safety using 2 different dosing regimens (N3I1=nivolumab 3mg/kg+ipilumumab 1mg/kg; N1I3=nivolumab 1mg/kg+ipilumumab 3mg/kg) in patients with metastatic renal cell carcinoma, and resulted in an objective response rate of 40.4% (19/47) in both N3I1 and N1I3 arms and a 2-year overall survival of 67% in the N3I1 arm and 70% in the N1I3 arm (PMID: 28678668; NCT01472081). | 28678668 |
| Unknown unknown | hepatocellular carcinoma | not applicable | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase I (CheckMate 040) trial that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was well tolerated, resulted in an objective response rate of 32% (16/50, 4 complete response, 12 partial response) with a median duration of response of 17 months in patients with hepatocellular carcinoma previously treated with Nexavar (sorafenib) (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 4012-4012; NCT01658878). | detail... detail... detail... |
| Unknown unknown | lung small cell carcinoma | not applicable | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org). | detail... |
| Unknown unknown | stomach cancer | not applicable | Ipilimumab + Nivolumab | Phase Ib/II | Actionable | In a Phase I/II trial, Opdivo (nivolumab), alone or incombination with Yervoy (ipilimumab), demonstrated safety and efficacy in patients with chemotherapy-refractory gastric cancer, resulted in a disease control rate of 38% (61/160) (J Clin Oncol 34, 2016 (suppl; abstr 4010)). | detail... |
| Unknown unknown | melanoma | not applicable | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) resulted in improved overall response rate (ORR) and pathologic complete response rate (pCR) compared to Opdivo (nivolumab) monotherapy in patients with stage III or IV melanoma, with a ORR of 73% (8/11) and pCR of 45% (5/11), however, demonstrated higher toxicity (PMID: 30297909; NCT02519322). | 30297909 |
| Unknown unknown | melanoma | not applicable | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase III trial (CheckMate 067) that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) and Opdivo (nivolumab) alone demonstrated improved efficacy compared to Yervoy (ipilimumab) in patients with untreated advanced melanoma, resulted in a median overall survival unreached in the combination arm, 36.9 and 19.9 months in nivolumab and ipilimumab monotherapy arms, and a median progression-free survival of 11.5, 6.9, and 2.9 months respectively (PMID: 30361170; NCT01844505). | detail... detail... 30361170 |
| Unknown unknown | clear cell renal cell carcinoma | not applicable | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (HCRN GU16-260), salvage therapy with combination of Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a partial response in 11% (3/27) and stable disease in 30% (8/27) of patients with advanced clear cell renal cell carcinoma whose disease progressed after Opdivo (nivolumab) monotherapy (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 5006-5006; NCT03117309). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT02659540 | Phase I | Ipilimumab + Nivolumab | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Active, not recruiting |
| NCT03597282 | Phase I | Ipilimumab + Nivolumab APX005M + Nivolumab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC APX005M + NEO-PV-01 + Nivolumab + Poly ICLC Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | Active, not recruiting |
| NCT03172624 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Recruiting |
| NCT03461952 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) | Active, not recruiting |
| NCT03646617 | Phase II | Ipilimumab + Nivolumab | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | Recruiting |
| NCT02939300 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma | Active, not recruiting |
| NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Recruiting |
| NCT03749460 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | Recruiting |
| NCT02714218 | Phase III | Ipilimumab + Nivolumab | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | Active, not recruiting |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Active, not recruiting |
| NCT03670056 | Phase II | Ipilimumab + Nivolumab | A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy | Recruiting |
| NCT03130959 | Phase II | Ipilimumab + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Active, not recruiting |
| NCT03138512 | Phase III | Ipilimumab + Nivolumab | A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) | Recruiting |
| NCT03425292 | Phase I | Temozolomide Ipilimumab + Nivolumab Nivolumab | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | Recruiting |
| NCT03033576 | Phase II | Ipilimumab Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery | Active, not recruiting |
| NCT02785952 | Phase III | Nivolumab Ipilimumab + Nivolumab | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting |
| NCT03143153 | Phase III | Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Active, not recruiting |
| NCT03162731 | Phase I | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer | Active, not recruiting |
| NCT02982954 | Phase III | Ipilimumab + Nivolumab | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) | Active, not recruiting |
| NCT03693846 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Recruiting |
| NCT04039607 | Phase III | Lenvatinib Sorafenib Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | Recruiting |
| NCT03146650 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer | Active, not recruiting |
| NCT03789110 | Phase II | Ipilimumab + Nivolumab | NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | Recruiting |
| NCT02864251 | Phase III | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) | Recruiting |
| NCT03203473 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Active, not recruiting |
| NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Active, not recruiting |
| NCT03903640 | Phase II | Ipilimumab + Nivolumab | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | Recruiting |
| NCT03651271 | Phase II | Ipilimumab + Nivolumab Nivolumab | Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer | Recruiting |
| NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Recruiting |
| NCT03220009 | Phase II | Ipilimumab + Nivolumab | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Withdrawn |
| NCT03420521 | Phase II | Ipilimumab + Nivolumab | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Recruiting |
| NCT03799445 | Phase II | Ipilimumab + Nivolumab | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Recruiting |
| NCT04495010 | Phase II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) | Not yet recruiting |
| NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA) | Active, not recruiting |
| NCT03377361 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread | Active, not recruiting |
| NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma | Recruiting |
| NCT03256136 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab | A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer | Completed |
| NCT03377023 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | Recruiting |
| NCT03274258 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | Recruiting |
| NCT03158129 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection | Recruiting |
| NCT04323046 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Not yet recruiting |
| NCT03918252 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Recruiting |
| NCT03223155 | Phase I | Ipilimumab + Nivolumab | Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer | Recruiting |
| NCT03425331 | Phase II | Ipilimumab + Nivolumab | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Suspended |
| NCT04013542 | Phase I | Ipilimumab + Nivolumab Nivolumab | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer | Active, not recruiting |
| NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Active, not recruiting |
| NCT03367715 | Phase II | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | Recruiting |
| NCT04429321 | Phase I | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | Not yet recruiting |
| NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting |
| NCT02656706 | Phase II | Ipilimumab + Nivolumab | BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial | Recruiting |
| NCT03305445 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | Recruiting |
| NCT03071406 | Phase II | Ipilimumab + Nivolumab | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | Recruiting |
| NCT03724968 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | Active, not recruiting |
| NCT03463408 | Phase I | Ipilimumab + Nivolumab | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Recruiting |
| NCT02599402 | Phase III | Ipilimumab + Nivolumab Nivolumab | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | Active, not recruiting |
| NCT03101566 | Phase II | Cisplatin + Gemcitabine + Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | Active, not recruiting |
| NCT02601014 | Phase II | Ipilimumab + Nivolumab | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | Active, not recruiting |
| NCT03600155 | Phase I | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia | Recruiting |
| NCT02231749 | Phase III | Ipilimumab + Nivolumab Sunitinib | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Active, not recruiting |
| NCT03575793 | Phase Ib/II | Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Recruiting |
| NCT04042753 | Phase II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | Recruiting |
| NCT02408861 | Phase I | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors | Recruiting |
| NCT02985957 | Phase II | Ipilimumab + Nivolumab | A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Recruiting |
| NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Recruiting |
| NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Recruiting |
| NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Active, not recruiting |
| NCT02350764 | Phase II | Ipilimumab + Nivolumab | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | Recruiting |
| NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Recruiting |
| NCT03528408 | Phase II | Ipilimumab + Nivolumab | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | Recruiting |
| NCT04118166 | Phase II | Ipilimumab + Nivolumab | Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | Recruiting |
| NCT03719131 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | Recruiting |
| NCT04007588 | Phase II | Ipilimumab + Nivolumab Nivolumab BMS-986205 + Nivolumab | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | Withdrawn |
| NCT02935634 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) | Recruiting |
| NCT04382664 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | Recruiting |
| NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting |
| NCT02996110 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) | Recruiting |
| NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting |
| NCT03029780 | Phase II | Ipilimumab + Nivolumab | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | Active, not recruiting |
| NCT02659059 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) | Active, not recruiting |
| NCT03570619 | Phase II | Ipilimumab + Nivolumab | Immunotherapy iImmunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) | Recruiting |
| NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Recruiting |
| NCT04465643 | Phase I | Ipilimumab + Nivolumab | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Not yet recruiting |
| NCT02970981 | Phase II | Ipilimumab + Nivolumab | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | Active, not recruiting |
| NCT02880020 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | Recruiting |
| NCT03036098 | Phase III | Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer | Recruiting |
| NCT03285321 | Phase II | Ipilimumab + Nivolumab Nivolumab | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT03065179 | Phase II | Ipilimumab + Nivolumab | Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients | Recruiting |
| NCT02186249 | Phase III | Ipilimumab + Nivolumab | Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) | No longer available |
| NCT03521830 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Recruiting |
| NCT02892734 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | Terminated |
| NCT03246958 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab in Thyroid Cancer | Recruiting |
| NCT04361162 | Phase II | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | Not yet recruiting |
| NCT03043599 | Phase Ib/II | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting |
| NCT03342417 | Phase II | Ipilimumab + Nivolumab | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Terminated |
| NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting |
| NCT04326257 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | Recruiting |
| NCT03117309 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | Recruiting |
| NCT02833233 | Phase I | Ipilimumab + Nivolumab | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | Active, not recruiting |
| NCT03122522 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | Recruiting |
| NCT04013854 | Phase II | Ipilimumab + Nivolumab Nivolumab | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Active, not recruiting |
| NCT03222076 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) | Active, not recruiting |
| NCT03707457 | Phase I | Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | Terminated |
| NCT02872116 | Phase III | Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) | Active, not recruiting |
| NCT03520491 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | Recruiting |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Recruiting |
| NCT02210117 | Phase II | Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab | Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) | Active, not recruiting |
| NCT02736123 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Withdrawn |
| NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Recruiting |
| NCT03391869 | Phase III | Ipilimumab + Nivolumab | Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR) | Recruiting |
| NCT03335540 | Phase I | BMS-986205 + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | Recruiting |
| NCT03203304 | Phase I | Nivolumab Ipilimumab + Nivolumab | Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma | Active, not recruiting |
| NCT02017717 | Phase III | Nivolumab Bevacizumab Ipilimumab + Nivolumab | A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) | Active, not recruiting |
| NCT02919683 | Phase II | Nivolumab Ipilimumab + Nivolumab | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Active, not recruiting |
| NCT03776487 | Phase Ib/II | Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Recruiting |
| NCT03668119 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | Recruiting |
| NCT02899299 | Phase III | Carboplatin + Cisplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Active, not recruiting |
| NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Recruiting |
| NCT03829111 | Phase I | Ipilimumab + Nivolumab CBM588 + Ipilimumab + Nivolumab | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | Recruiting |
| NCT03956680 | Phase I | Ipilimumab + Nivolumab BMS-986301 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | Recruiting |
| NCT02869789 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | Active, not recruiting |
| NCT02978443 | Phase II | Ipilimumab + Nivolumab | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | Active, not recruiting |
| NCT02998528 | Phase III | Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine | A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) | Active, not recruiting |
| NCT03937219 | Phase III | Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) | Recruiting |
| NCT03048136 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) | Withdrawn |
| NCT04340193 | Phase III | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) | Not yet recruiting |
| NCT02320058 | Phase II | Ipilimumab + Nivolumab | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) | Active, not recruiting |
| NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Not yet recruiting |
| NCT03798639 | Phase I | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Recruiting |
| NCT03001882 | Phase II | Ipilimumab + Nivolumab | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting |
| NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Recruiting |
| NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Recruiting |
| NCT03546686 | Phase II | Ipilimumab + Nivolumab | Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer | Recruiting |
| NCT03241186 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | Recruiting |
| NCT04088500 | Phase II | Ipilimumab + Nivolumab | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | Recruiting |
| NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) | Recruiting |
| NCT02224781 | Phase III | Ipilimumab + Nivolumab Dabrafenib + Trametinib | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Recruiting |
| NCT03873402 | Phase III | Nivolumab Ipilimumab + Nivolumab | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Recruiting |
| NCT02741570 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting |
| NCT03262779 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | Recruiting |
| NCT04090710 | Phase II | Nivolumab Ipilimumab + Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) | Recruiting |
| NCT03604978 | Phase Ib/II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma | Recruiting |
| NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Recruiting |
| NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Recruiting |
| NCT02823574 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting |
| NCT03126461 | Phase II | Ipilimumab + Nivolumab | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | Withdrawn |
| NCT03149159 | Phase II | Ipilimumab + Nivolumab | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | Withdrawn |
CKB BOOST